BRPI0817079A2 - processos para fabricação recombinante de anticorpos anti-rsv - Google Patents

processos para fabricação recombinante de anticorpos anti-rsv

Info

Publication number
BRPI0817079A2
BRPI0817079A2 BRPI0817079A BRPI0817079A BRPI0817079A2 BR PI0817079 A2 BRPI0817079 A2 BR PI0817079A2 BR PI0817079 A BRPI0817079 A BR PI0817079A BR PI0817079 A BRPI0817079 A BR PI0817079A BR PI0817079 A2 BRPI0817079 A2 BR PI0817079A2
Authority
BR
Brazil
Prior art keywords
processes
rsv antibodies
recombinant manufacture
recombinant
manufacture
Prior art date
Application number
BRPI0817079A
Other languages
English (en)
Portuguese (pt)
Inventor
Anne Bondgaard Tolstrup
Finn Wiberg
Johan Lantto
Lars Soegaard Nielsen
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of BRPI0817079A2 publication Critical patent/BRPI0817079A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0817079A 2007-09-07 2008-09-04 processos para fabricação recombinante de anticorpos anti-rsv BRPI0817079A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200701289 2007-09-07
PCT/DK2008/050218 WO2009030237A2 (en) 2007-09-07 2008-09-04 Methods for recombinant manufacturing of anti-rsv antibodies

Publications (1)

Publication Number Publication Date
BRPI0817079A2 true BRPI0817079A2 (pt) 2016-10-11

Family

ID=40297785

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817079A BRPI0817079A2 (pt) 2007-09-07 2008-09-04 processos para fabricação recombinante de anticorpos anti-rsv

Country Status (13)

Country Link
US (2) US20090137003A1 (enExample)
EP (1) EP2185590A2 (enExample)
JP (1) JP2011514139A (enExample)
KR (1) KR20100087283A (enExample)
CN (1) CN101821289A (enExample)
AU (1) AU2008295248A1 (enExample)
BR (1) BRPI0817079A2 (enExample)
CA (1) CA2695309A1 (enExample)
MX (1) MX2010002044A (enExample)
RU (1) RU2010113510A (enExample)
TW (1) TW200925279A (enExample)
WO (1) WO2009030237A2 (enExample)
ZA (1) ZA201000756B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2032701T3 (da) * 2006-06-23 2014-02-10 Alethia Biotherapeutics Inc Polynukleotider og polypeptider, der er inddraget i cancer
ATE521704T1 (de) * 2007-03-01 2011-09-15 Symphogen As Verfahren zur klonierung verwandter antikörper
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2331689A4 (en) * 2008-08-29 2012-10-31 Symphogen As METHOD OF CLONING AVIAN ORIGIN ANTIBODIES
JP5781932B2 (ja) 2008-11-03 2015-09-24 アレシア・バイオセラピューティクス・インコーポレーテッド 腫瘍抗原の生物活性を特異的にブロックする抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
CN102656189B (zh) * 2009-08-13 2014-10-08 克鲁塞尔荷兰公司 针对人呼吸道合胞病毒(rsv)的抗体以及使用方法
CN104628850B (zh) * 2009-10-06 2020-07-28 医学免疫有限公司 Rsv-特异性结合分子
JP5734988B2 (ja) * 2009-10-06 2015-06-17 メディミューン リミテド Ｒｓｖ特異的結合分子
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN104131035A (zh) 2009-12-10 2014-11-05 瑞泽恩制药公司 生产重链抗体的小鼠
NZ703035A (en) 2010-07-09 2016-06-24 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EP2691421B1 (en) 2011-03-31 2016-11-09 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
EA201992513A1 (ru) 2012-01-09 2020-05-31 Адс Терапьютикс Са Способ лечения рака груди
AR092219A1 (es) * 2012-08-23 2015-04-08 Seattle Genetics Inc Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7
JP5996707B2 (ja) * 2015-04-15 2016-09-21 メディミューン リミテド Ｒｓｖ特異的結合分子
PH12017502013B1 (en) 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
EP3383914A4 (en) * 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHOD OF USE THEREOF
WO2017096182A1 (en) * 2015-12-03 2017-06-08 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
EP3529272A2 (en) 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3974447A3 (en) 2016-10-21 2022-09-07 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP2020503844A (ja) 2016-10-21 2020-02-06 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018150029A1 (en) * 2017-02-17 2018-08-23 Institut Pasteur Generation of monoclonal antibodies targeting respiratory syncytial virus (rsv) using regulatory b cells from newborns (nbregs)
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
WO2021253002A1 (en) 2020-06-12 2021-12-16 Gigagen, Inc. Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2022031834A1 (en) 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
WO2006007850A1 (en) * 2004-07-20 2006-01-26 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
CA2574146C (en) * 2004-07-20 2015-06-30 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
AU2006322445B2 (en) * 2005-12-05 2011-05-12 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
KR20080113223A (ko) * 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
WO2008106980A2 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
MX2009012526A (es) * 2007-05-25 2009-12-09 Symphogen As Metodo para fabricar una proteina policlonal recombinante.

Also Published As

Publication number Publication date
WO2009030237A2 (en) 2009-03-12
AU2008295248A1 (en) 2009-03-12
RU2010113510A (ru) 2011-10-20
US20090137003A1 (en) 2009-05-28
JP2011514139A (ja) 2011-05-06
US20120009623A1 (en) 2012-01-12
CN101821289A (zh) 2010-09-01
WO2009030237A3 (en) 2009-04-30
MX2010002044A (es) 2010-03-18
TW200925279A (en) 2009-06-16
EP2185590A2 (en) 2010-05-19
ZA201000756B (en) 2010-10-27
CA2695309A1 (en) 2009-03-12
KR20100087283A (ko) 2010-08-04

Similar Documents

Publication Publication Date Title
BRPI0817079A2 (pt) processos para fabricação recombinante de anticorpos anti-rsv
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0923359A2 (pt) Anticorpos anti-igf
BRPI0819165A2 (pt) Anticorpos anti-vegf
BRPI0918838A2 (pt) processos para preparação de composições de polipeptídeos purificados
BR112013008738A2 (pt) processos para purificação de proteínas
BRPI0917204A2 (pt) variantes estruturais de anticorpos para melhores características terapêuticas
DK2488867T3 (da) Fremgangsmåder til affinitetsmodning af antistoffer
DK2643018T3 (da) Anti-il-6-antistoffer til behandling af oral mucositis
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
EP2222710A4 (en) RECOMBINANT RSV ANTIGEN
DK2059533T3 (da) Multispecifikke antistoffer
SMT201700083B (it) Anticorpi monoclonali
EP2473531A4 (en) Anti-gitr antibodies
PT2406284T (pt) Anticorpos anti-bcma
ZA200905990B (en) Recombinant antibodies for treatment of respriratory syncytial virus infections
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
DK2066695T3 (da) Anti-myostatin-antistoffer
EP2429627A4 (en) METHOD FOR PRODUCING MICROPROJECTION ARRAYS
BRPI1011005A2 (pt) anticorpos anti-epcam
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
EP2217079A4 (en) CASEIN-PRODUCTION
CR10705A (es) Anticuerpos para linfotoxina-alfa
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]